• Andrea Salmaggi, Amerigo Boiardi, Maurizio Gelati, Annamaria Russo, Chiara Calatozzolo, Emilio Ciusani, Francesca Luisa Sciacca, Arianna Ottolina, Eugenio Agostino Parati, Caterina La Porta, Giulio Alessandri, Carlo Marras, Danilo Croci, and Marco De Rossi.
• Istituto Nazionale Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy. salmaggi@istituto-besta.it
• Glia. 2006 Dec 1; 54 (8): 850-60.

AbstractWe investigated in vitro the properties of selected populations of cancer stem-like cells defined as tumorospheres that were obtained from human glioblastoma. We also assessed their potential and capability of differentiating into mature cells of the central nervous system. In vivo, their tumorigenicity was confirmed after transplantation into the brain of non-obese diabetic/severe combined immunodeficient (NOD-SCID) mice. The angiogenic potential of tumorospheres and glioblastoma-derived cells grown as adherent cells was revealed by evaluating the release of angiogenic factors such as vascular endothelial growth factor and CXCL12 by ELISA, as well as by rat aortic ring assay. The proliferative response of tumorospheres in the presence of CXCL12 was observed for the first time. Multidrug resistance-associated proteins 1 and 3 as well as other molecules conferring multidrug resistance were higher when compared with primary adherent cells derived from the same tumor. Finally, we obtained cells from the tumor developing after grafting that clearly expressed the putative neural stem cell marker CD133 as shown by FACS analysis and also nestin and CXCR4. The cells' positivity for glial fibrillary acidic protein was very low. Moreover these cells preserved their angiogenic potential. We conclude that human glioblastoma could contain tumor cell subsets with angiogenic and chemoresistance properties and that this chemoresistance potential is highly preserved by immature cells whereas the angiogenic potential is, to a higher extent, a property of mature cells. A better understanding of the features of these cell subsets may favor the development of more specifically targeted therapies.(c) 2006 Wiley-Liss, Inc.

63 keywords...

hide…